Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hasten Biopharmaceuticals
Hefei, Anhui, Chinahastenpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Hasten is actively commercializing established chronic and cardiovascular disease therapies across Asia-Pacific, and developing late-stage assets such as Lerodalcibep (PCSK9 inhibitor) for lowering LDL-cholesterol; extensive pipeline expansion through strategic acquisitions from Takeda and Celltrion, with bridging studies ongoing in China for new approvals[2][5][8].
- Therapeutic areas
- EndocrinologyMetabolic DisordersCardiovascular
- Modalities
- Small moleculeFusion proteinProtein
- Industry
- Biotech
02
Partnerships
Takeda (licensing of 5 cardiovascular & metabolism drugs)[4]Celltrion (acquisition of 14 branded products across Pan-Asia)[5][8]LIB Therapeutics (Lerodalcibep development/commercialization in China)[2][6]
Beyond the preview
Go deeper on Hasten Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hasten Biopharmaceuticals.